SCHEMBL15399963

SCHEMBL15399963

C1CC2(CCN1)CCO2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30282623 0.97 MEN1 (0.32)
SCHEMBL25330537 0.91 MEN1 (0.38)
SCHEMBL16878728 0.89 CXCR4 (0.32)
SCHEMBL16877710 0.88
SCHEMBL16878327 0.87 ALDH1A1 (0.36)
SCHEMBL255188 0.86
Oxalic Acid SCHEMBL21590826 0.85 KDM4E (0.32)
Oxalic Acid SCHEMBL21590825 0.85 KDM4E (0.32)
SCHEMBL16878730 0.84 CXCR4 (0.32)
Hydrochloric Acid SCHEMBL4689253 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4554939-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2025-05-21 EP claimed
CN-119604494-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2025-03-11 CN claimed
WO-2024013209-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-01-18 WO claimed
EP-3693368-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-12-06 EP claimed
US-11407748-B2 Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-08-09 US claimed
EP-3911648-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP claimed
EP-3911640-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP claimed
US-20200270243-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-08-27 US claimed
EP-3693368-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-08-12 EP claimed
WO-2020150474-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO claimed
WO-2020150473-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO claimed
WO-2026106912-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-05-21 WO disclosed
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 EP disclosed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 US disclosed
WO-2015103583-A1 MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-07-09 WO disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
US-8809359-B2 Phenyl amino pyrimidine bicyclic compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (US) 2014-08-19 US disclosed
US-20140005161-A1 PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF YM BIOSCIENCES AUSTRALIA PTY LTD (US) 2014-01-02 US disclosed